Publications
- Aggressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment: a case report2020 | Faculty of Medicine in Pilsen
- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- Pneumooncology in case reports - successes and controversies in thoracic oncology2018 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Do metastases in the brain in a tumor with ALK translocation always mean ineffectiveness of crizotinib therapy?2017 | Faculty of Medicine in Pilsen
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | Faculty of Medicine in Pilsen, Faculty of Science, First Faculty of Medicine
- Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib2016 | Faculty of Medicine in Pilsen
- Nintedanib - interesting alternative forsecond line pulmonaty adenocarcinoma patients2016 | Faculty of Medicine in Pilsen
- The coincidence of tumorlets and metastases of lung in a patient with a history of malignant melanoma2016 | Faculty of Medicine in Pilsen
- Tumor Rebiopsy - Guide to Targeted Therapy2016 | Faculty of Medicine in Pilsen
Loading network view...